Attempts to produce a vaccine to protect against -induced trachoma were initiated more than 100 years ago and continued for several decades. Using whole organisms, protective responses were obtained. However, upon exposure to , disease exacerbation developed in some immunized individuals, precluding the implementation of the vaccine. Evidence of the role of as a sexually transmitted pathogen started to emerge in the 1960s, and it soon became evident that it can cause acute infections and long-term sequelae in women, men, and newborns. The main focus of this minireview is to summarize recent findings and discuss formulations, including antigens, adjuvants, routes, and delivery systems for immunization, primarily explored in the female mouse model, with the goal of implementing a vaccine against genital infections.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382834 | PMC |
http://dx.doi.org/10.1128/CVI.00543-16 | DOI Listing |
Am J Emerg Med
November 2024
Department of Emergency Medicine, University of Louisville School of Medicine, 550 S Jackson St., Louisville, KY 40202, USA.
Background: Chlamydia trachomatis is the most prevalent, reportable sexually transmitted infection (STI) in the United States. In 2021, the Centers for Disease Control and Prevention (CDC) updated treatment recommendations from a single azithromycin 1000 mg dose to doxycycline 100 mg twice daily for seven days for the treatment of chlamydia infections. In response to changes in treatment recommendations and addressing patient barriers to treatment, pharmacists at an urban, academic medical center collaborated with the state health department to create doxycycline kits dispensed upon emergency department (ED) discharge.
View Article and Find Full Text PDFPathog Dis
February 2024
Institute of Veterinary Pathology, University of Zurich, 8057 Zurich, Switzerland.
The obligate intracellular bacterial genus Chlamydia harbours species with zoonotic potential, particularly C. psittaci, causative agent of psittacosis, and C. abortus, which may lead to miscarriage in pregnant women.
View Article and Find Full Text PDFNew Microbiol
November 2024
Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy.
Chlamydia pneumoniae is the etiologic agent of respiratory tract infections in humans, including community-acquired pneumonia, and has been associated with atherosclerotic cardiovascular diseases. The present systematic review of reviews aimed at answering important questions on the involvement of C. pneumoniae in the pathogenesis of atherosclerosis, its cellular and molecular mechanisms, and whether there is evidence of a causal relationship.
View Article and Find Full Text PDFVirulence
December 2024
Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China; Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang, Hunan, China.
is an obligate intracellular gram-negative bacterium with a unique biphasic developmental cycle. It is a zoonotic pathogen with a wide range of hosts and can cause avian chlamydiosis in birds and psittacosis in humans. The pathogen is transmitted mainly through horizontal transmission between birds.
View Article and Find Full Text PDFAnimals (Basel)
October 2024
Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!